Market Herald logo


Be the first with the news that moves the market

HeraMED limited expand its HeraBEAT product after launching a UK website. The med-tech company’s product allows mothers and doctors to monitor infant heart rates during pregnancy.

HeraBEAT was previously unavailable to UK consumers but available in Israel. HeraMED assesses 770,000 UK births annually, making this expansion their largest market entry yet.

The expansion was made after positive feedback from UK doctors and Israeli consumers. The product also features an integrated mobile app.

Professional discussion included feedback from senior obstetricians and gynecologists in public hospitals and private medical institutions.

HeraMED CEO David Groberman says the company is well ahead of commercial scale.

“[The company] is progressing discussions with a number of parties globally to progress its international expansion, [we look] forward to updating shareholders on these developments in the coming months,” he said.

The company plans to use UK revenue for further expansion across Europe.

The company is currently in discussion with more medical institutions to strengthen professional use.

HeraMED plans for global expansion in the coming months.

Please see the announcement

HMD by the numbers
More From The Market Herald

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.